Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $22.50.

Several equities analysts have commented on the company. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Delcath Systems in a report on Friday, January 9th. Stephens decreased their price objective on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Evercore set a $27.00 price objective on shares of Delcath Systems in a research report on Thursday, February 26th.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of CHOPIN Phase 2 trial in The Lancet Oncology — The full, investigator‑initiated CHOPIN randomized Phase 2 results led by Prof. Ellen Kapiteijn were published, increasing clinical visibility and credibility for Delcath’s liver‑directed chemotherapy platform; this type of high‑profile peer‑reviewed publication can support investor confidence and future regulatory/commercial discussions. Article Title Business Wire Release
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $30 price target — the firm continues to show long‑term conviction even as it revises near‑term numbers, which may temper negative reactions relative to a full downgrade.
• Neutral Sentiment: Long‑range forecasts mixed — HC Wainwright published multi‑year model estimates (including a new FY2030 EPS projection), showing a path to profitability further out; these farther‑out estimates are informative but less likely to move the stock as much as near‑term revisions.
• Neutral Sentiment: Short interest report shows no meaningful data change — the reported short interest figures appear to be zero/erroneous and do not indicate increased short pressure at this time.
• Negative Sentiment: Multiple downward EPS revisions from HC Wainwright — the analyst cut Q1–Q4 2026 and FY2026 estimates significantly (examples: Q1 from $0.13 to ($0.01), Q2 from $0.08 to ($0.15), Q3 from $0.10 to ($0.42), and FY2026 from $0.58 to ($0.86)), and lowered FY2027‑FY2029/FY2028/FY2029 forecasts as well. Those near‑term cuts increase uncertainty about upcoming quarters and could limit upside despite the trial publication.

Delcath Systems Price Performance

Delcath Systems stock opened at $9.23 on Monday. The firm has a market capitalization of $320.74 million, a P/E ratio of 131.86 and a beta of 0.38. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $18.23. The company’s 50-day moving average is $9.91 and its 200 day moving average is $10.16.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%.The firm had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $20.35 million. Research analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Delcath Systems announced that its board has authorized a stock buyback plan on Thursday, November 20th that authorizes the company to buyback $25.00 million in shares. This buyback authorization authorizes the company to buy up to 8.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DCTH. XTX Topco Ltd raised its position in Delcath Systems by 339.4% during the 4th quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock valued at $719,000 after purchasing an additional 54,990 shares in the last quarter. Millennium Management LLC increased its stake in shares of Delcath Systems by 3.0% during the fourth quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock valued at $2,489,000 after buying an additional 7,190 shares during the period. Man Group plc raised its holdings in shares of Delcath Systems by 34.1% in the fourth quarter. Man Group plc now owns 38,158 shares of the company’s stock valued at $385,000 after acquiring an additional 9,705 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of Delcath Systems by 69.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock valued at $527,000 after acquiring an additional 21,384 shares in the last quarter. Finally, Jump Financial LLC lifted its stake in Delcath Systems by 68.0% in the fourth quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock worth $464,000 after acquiring an additional 18,596 shares during the period. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.